Next week, a CMS committee will hold a daylong meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell immunotherapies, the game-changing cancer treatment approved by the FDA for 2 indications, and being studied for more. The request for an NCD was put forth by UnitedHealthcare, the nation’s largest insurer and...Continue Reading
Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he’s ready for his experimental treatment. “How’s your night? Any issues?” asks Dr. Katherine Barnett, a pediatric oncologist, as they begin to examine Reid. Reid, 20, of Lucedale, Miss., has been fighting leukemia...Continue Reading
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more: https://www.biopharma-reporter.com/Article/2018/08/15/US-FDA-approves-first-non-gene-edited-allogeneic-CAR-T-cell-candidate-for-trials?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyrightContinue Reading
Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma (NDMM) compared with other regimens in the maintenance setting, according to a study published in JAMA Oncology.1 Many agents have demonstrated efficacy as maintenance agents in patients with NDMM. Due to a lack of comparative...Continue Reading
University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells. CAR-T therapy has been called a “living drug” and is part of a rapidly emerging immunotherapy approach called adoptive cell transfer (ACT), which collects...Continue Reading
Children treated with chimeric antigen receptor T-cell therapy experience unique toxicities that require careful monitoring to prevent serious sequalae, according to new management guidelines. An educated interdisciplinary team — including nurses, trainees, intensivists and cell therapists — is essential to identify early signs and symptoms of cytokine release syndrome (CRS) and chimeric antigen receptor (CAR)-T-cell-related...Continue Reading
Panelists: A. Keith Stewart, MB, ChB, Mayo Clinic; Sagar Lonial, MD, FACP, Emory University School of Medicine; Thomas Martin, MD, UCSF Helen Diller Family; Edward A. Stadtmauer, MD, University of Pennsylvania; Ajai Chari, MD, Mount Sinai Hospital; Amrita Krishnan, MD, FACP, City of Hope Cancer Center Published: Tuesday, Aug 14, 2018 Continue Reading
When it comes to multiple myeloma, patients’ bone health can have major implications on their outcomes – even before they are diagnosed, according to recent research conducted by Ashley Rosko, M.D. Rosko, who is an assistant professor at The Ohio State University Comprehensive Cancer Center, and her team used the Women’s Health Initiative (WHI) to...Continue Reading
A collaborative project in the UK between researchers from the University of Oxford, the University of Exeter and Chiddenbrook Surgery, Crediton, could lead to GPs using simple blood tests to improve the early diagnosis of myeloma. The study investigated the best combination of blood tests that could be used to diagnose the rare cancer within...Continue Reading
